Business Wire

NE-DESIGN-DATA

23.5.2017 14:02:47 CEST | Business Wire | Press release

Share
Design Data's SDS/2 2016 Earns SCI Assessed Status

Design Data, a leader in 3D steel detailing and Building Information Modeling (BIM) software, announced that the Steel Construction Institute (SCI) has recently assessed Design Data’s SDS/2 2016 software for connection design.

SDS/2 takes a uniquely intelligent approach in its connection design by considering framing conditions and erectability, automatically performing clash prevention as a part of its connection design. In addition, SDS/2 can value engineer the connections on a project, helping users to design the most economical connections to fabricate and erect.

SCI’s process involved reviewing connection design output in depth for each connection type: partial depth end plates, fin plates, column splices, beam splices, bracing connections, and bolted moment connections (end plates). Each connection was reviewed in detail for numerical correctness for the specific arrangement, but also to demonstrate that important principles common to all connections were correctly implemented.

SCI’s assessment was made in accordance with Eurocode 3: Design of steel structures, BS EN 1993, and the relevant UK National Annexes. Additionally, the “Green Books” were used as reference documents, being referenced in the U.K. National Annex and the de facto standard in the U.K.

“Achieving SCI Assessed status is a key advantage for us entering the U.K. and European markets,” said Damon Scaggs, president of Design Data. “With incorporating European design codes for the first time into SDS/2 — which already implements American, Canadian and Australian design codes — it was important to subject the software to the rigorous and extensive testing SCI conducted. This will help give our new European customers the confidence in our connections that our customers around the world have had for more than 30 years.”

According to the SCI Assessed website, “SCI Assessed” is an established quality mark that is awarded to testify that manufacturers' technical data has been independently verified by SCI. The scheme provides reliability for the range of performance data offered by suppliers particularly where, for example, the product is new or the values are based on calculation methods outside the scope of established standards.

About Design Data

Design Data, a Nemetschek company, is a leading software innovator for the steel industry's fabrication, detailing and engineering sectors. SDS/2 software products provide automatic connection optimization, detailing, engineering information, fabrication data and much more, reducing the time required to design, detail, fabricate and erect steel. Founded in 1981 and headquartered in Lincoln, Nebraska, USA, the company serves customers in 17 countries. Information on Design Data and SDS/2 can be found at: www.sds2.com .

About SCI

SCI has been a trusted, independent source of information and engineering expertise globally for over 30 years, and remains the leading, independent provider of technical expertise and disseminator of best practice to the steel construction sector. SCI offers comprehensive advice, technical information, consultancy services and membership for manufacturers, engineers and designers for every aspect of steel construction.

Contact:

Design Data
Damon Scaggs, 402-441-4000
President
Fax: 402-441-4045
damon@sds2.com
www.sds2.com

Link:

ClickThru

About Business Wire

Business Wire
Business Wire
101 California Street, 20th Floor
CA 94111 San Francisco

http://businesswire.com

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

Doubtless Pet Care Launches to Provide Peace of Mind to Pet Parents and Help Their Pets Live Happier, Healthier Lives29.6.2026 10:15:00 CEST | Press release

Doubtless combines industry-leading pet insurance with innovative care solutions, protecting more than 6 million pets across 10 global markets Doubtless launches today with the goal of helping more pet parents across the world access quality care for the pets they love. The company brings together a leading global portfolio of pet insurance brands with a growing range of connected solutions designed to support pet parents at every stage of their pet’s life. With over 4,000 employees, Doubtless insures 6 million pets across 10 markets in North America, Europe and the United Kingdom. “Uncertainty about the financial commitments associated with having a pet should never keep families from experiencing the joy of a life with pets,” said Dirk Beeckman, CEO of Doubtless. “By harnessing the power of our international footprint, we are building on our leadership in pet insurance to create a global suite of solutions for pet parents, veterinarians and industry partners that makes pet care easie

Samsung Bioepis Announces Positive Preliminary Phase 1 and Phase 3 Data for SB27, a Proposed Biosimilar to Keytruda (Pembrolizumab)29.6.2026 09:19:00 CEST | Press release

Phase 1 study demonstrated pharmacokinetic (PK) equivalence between SB27 and Keytruda; Phase 3 study demonstrated equivalent objective response rate (ORR) at Week 24Phase 1 and Phase 3 studies expected to be completed within 2026 Samsung Bioepis Co., Ltd. announced today that the Phase 1 and Phase 3 studies on SB27, a proposed biosimilar to Keytruda1 (pembrolizumab), have met their primary endpoints. “We are excited to announce preliminary results from the Phase 1 and Phase 3 studies for SB27, our pembrolizumab biosimilar candidate. These topline positive results reinforce our scientific expertise and leadership in biosimilar development,” said Donghoon Shin, Executive Vice President and Head of Clinical Sciences Division at Samsung Bioepis. “We are on track to complete both Phase 1 and Phase 3 studies within this year. Leveraging our robust quality management system, we remain committed to advancing our biosimilar portfolio to broaden access to life-saving biologic medicines for patie

IQM Named a Major Player in the IDC MarketScape: Worldwide Quantum Computing 2026 Vendor Assessment29.6.2026 09:00:00 CEST | Press release

IQM today announced it has been named a Major Player in the IDC MarketScape: Worldwide Quantum Computing 2026 Vendor Assessment. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260629748732/en/ IQM named a major player in the IDC MarketScape IQM believes this recognition comes as institutions worldwide move quantum computing out of shared cloud access and into infrastructure they own and operate themselves. IQM calls this Production Quantum: full-stack, open-architecture superconducting systems deployed on premises, inside customers' own data centers and HPC environments, where organizations own the hardware, build internal expertise, and run quantum processors alongside their existing classical infrastructure. According to the IDC MarketScape, "For institutions building long-term quantum programs, this means the workflows and intellectual property developed on IQM hardware remain portable." The report further advises: "Consi

Zambon Announces Positive CHMP Opinion for Hopledo® (IPX203) for Adults with Parkinson’s Disease and Moderate to Severe Motor Fluctuations29.6.2026 09:00:00 CEST | Press release

Positive CHMP opinion is based on data from the Phase 3 RISE-PD trial, which demonstrated significantly more “Good ON” time with fewer daily doses compared with immediate-release levodopa/carbidopa More than one million people are living with Parkinson’s disease in the European Union, and over 80% experience motor fluctuations during the course of their disease, highlighting the need for additional treatment options Hopledo® contains a unique formulation combining immediate-release granules and extended-release pellets, providing both a rapid onset of action and a longer duration of effect, sustaining the levodopa therapeutic effect for a longer period of time If approved, Zambon expects to make Hopledo® progressively available to patients with Parkinson’s disease across Europe starting October 2026 Zambon today announced that the Committee for Medicinal Products for Human Use (CHMP) has adopted a positive opinion recommending the granting of a marketing authorization by the European M

Enhertu® Approved in the EU as First Tumor Agnostic HER2 Directed Therapy and Antibody Drug Conjugate for Patients with Previously Treated HER2 Positive Metastatic Solid Tumors29.6.2026 08:30:00 CEST | Press release

Approval based on three phase 2 trials of Daiichi Sankyo and AstraZeneca’s Enhertu that demonstrated clinically meaningful responses across a broad range of tumors Enhertu now approved for six indications in the EU Enhertu® (trastuzumab deruxtecan) has been approved in the European Union (EU) as a monotherapy for the treatment of adult patients with unresectable or metastatic HER2 positive (immunohistochemistry [IHC] 3+) solid tumors who have received prior treatment and who have no satisfactory treatment options. Enhertu is a specifically engineered HER2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The approval by the European Commission follows the positive opinion of the Committee for Medicinal Products for Human Use of the European Medicines Agency and is based on results from subgroups of patients with HER2 positive (IHC 3+) tumors across thr

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye